🔎︎
Walgreens announced on February 26, 2026, the launch of Walgreens Weight Management, a program offering on-demand virtual visits with clinicians and access to GLP-1 prescriptions as part of a personalized weight loss plan. Reported by Healthcare Brew, the program charges $49 per visit with no monthly fee and is currently available in 28 states. It is designed specifically for self-pay patients whose employer-sponsored insurance does not cover GLP-1 medications for weight loss.
The coverage gap is substantial. According to KFF data cited in the report, only about 20% of large employers currently cover GLP-1s for weight loss, leaving a significant portion of the population navigating those costs out of pocket. Walgreens is also offering Novo Nordisk's Wegovy in pill and injection form through its Rx Savings Finder tool at $149 and $199 per month, respectively.
The launch positions Walgreens directly against telehealth competitors such as Ro and Hims & Hers. Hims & Hers reported $2.3 billion in revenue for 2025, up 59% from the prior year, with growth largely attributed to compounded GLP-1 sales. That business model has, however, faced legal pressure following disputes over compounded versions of branded products.
Analysts cited in the report view Walgreens as a credible market entrant given its extended telehealth hours, seven days a week from 7 a.m. to 11 p.m. Central, and the absence of a subscription fee. JPMorgan Global Research projects the GLP-1 market will reach $200 billion by 2030.
The program's rollout follows Sycamore Partners' acquisition of Walgreens, which has also included staff reductions and internal restructuring.
